Navigation Links
Life Sciences Entrepreneurs S.L.U. Announces the First Financing of the Antiplatelet Candidate NmC by Spanish and Swiss Investors
Date:11/5/2012

BARCELONA, Spain, November 5, 2012 /PRNewswire/ --

Life Science Entrepreneurs S.L.U., a company dedicated to the early-stage development of high-risk/very high return ventures, announced today the conclusion of a first investment for an antiplatelet drug candidate code-named NmC.

Private investors from Barcelona, Geneva and Basel, all active in medical applications of life sciences, have funded the assays to confirm the safety and efficacy of the cardiovascular drug NmC.

"NmC might prevent cardiovascular incidents thanks to the unique way it dilutes the blood of at-risk patients", said François Arcand, President of Life Science Entrepreneurs S.L.U. "The drug candidate catches the interest of experts in the field because its novel mechanism of action could set it apart from antiplatelets like the standard-of-care Plavix® or the newcomer Eliquis®".

The molecule has been licensed from a foreign university. In early 2013, Life Science Entrepreneurs S.L.U. will raise two million euro to conduct a complete set of regulatory pre-clinical assays from Spanish and foreign investors.

About …

Life Science Entrepreneurs S.L. develops scientific discoveries up to the completion of a viable proof-of-concept, when successful technologies are susceptible to be acquired by well-funded specialized organizations.  For more, see http://www.LifSciE.com

Français : http://www.lifscie.com/fr/enemce/

Español: http://www.lifscie.com/es/enemce/

Català : http://www.lifscie.com/cat/en/enemce/


'/>"/>
SOURCE Life Science Entrepreneurs S.L.U.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Advantages of Pressure BioSciences PCT Platform Highlighted at a Recent International Scientific Conference Focused on the Role of Proteins in the Cause, Prevention, and Treatment of Disease
2. Parios Regenerative Sciences, Inc. Licenses Exclusive Rights to Organic Nanotechnology for Skin Repair
3. Keynote Presentation at Upcoming International Microbiology & Genomics Meeting to Highlight Ability of Pressure BioSciences Patented PCT Platform to Improve Testing for Biological Threat Organisms, Human Infectious Diseases, and Contaminated Food P
4. Amarantus BioSciences Announces MANF Demonstrates Superiority over GDNF in Neurorestoration Behavioural Animal Model of Parkinsons Disease
5. Call for Submissions: ICAP Patent Brokerage Announces Expansion of Life Sciences Practice and Increased Buyer Interest in Related Intellectual Property
6. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2012 Financial Results
7. Trovagene and Strand Life Sciences Agree to Validate and Commercialize Urine-Based HPV Test in India and South Asia
8. Arena Pharmaceuticals to Present at the UBS Global Life Sciences Conference
9. Rigel to Present at UBS Global Life Sciences Conference
10. HeartWare Presentation at the UBS Global Life Sciences Conference to be Webcast
11. Avanir Pharmaceuticals To Present At UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements ... announced tender offer by its indirect wholly-owned subsidiary, Sapphire ... of common stock of Solta Medical, Inc. (NASDAQ: ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... market research report is available in ... Global Markets and Technologies for Advanced ... Routes of Administration ...
(Date:1/15/2014)... FRANKLIN, Ohio , Jan. 15, 2014  A novel wearable ... it easy and painless for patients to self-inject prescription drugs ... of disorders, including cancer, blood diseases, autoimmune deficiencies, and genetic ... expected to grow to $220B by 2018, according to analysts.   ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2
... , SWARTZ CREEK, Mich., Nov. 17 Diplomat Specialty ... Bernardino, CA . Diplomat has 6 additional locations in ... contracts with managed care organizations in California will potentially impact ... Managed Care. "Our new San Bernardino location is an important ...
... , SOUTH SAN FRANCISCO, Calif., Nov. 17 ... announced updated clinical data from its randomized, controlled Phase ... cancer (CRC). The updated results indicated that picoplatin, ... and leucovorin in the FOLPI regimen, has comparable efficacy ...
Cached Medicine Technology:Diplomat Specialty Pharmacy Continues to Expand - Opens Location in Southern California 2Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results 2Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results 3Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results 4Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results 5
(Date:4/18/2014)... Fraser University psychologists have made a brain-related discovery ... attention-deficit disorders. , This discovery opens up the ... or suppress a specific brain activity that the ... , The Journal of Neuroscience has ... John McDonald, an associate professor of psychology and ...
(Date:4/17/2014)... signs of chronic inflammation in non-cancerous prostate tissue may ... cancer than those with no inflammation, according to results ... Johns Hopkins Kimmel Cancer Center. , The link between ... with so-called high-grade prostate cancer those with a ... presence of the most aggressive and rapidly growing prostate ...
(Date:4/17/2014)... April issue of Experimental Biology and Medicine ... Rex Gaskins and Paul Kenis in the Institute ... the University of Illinois Urbana-Champaign describe their recent ... underlie a variety of cell functions including energy ... crucial roles in regulating normal cellular behavior, redox ...
(Date:4/17/2014)... created a new technology for modifying human cells ... body and selectively target cancer and other sites ... monitor and modify human physiology is a promising ... technology enabled bioengineers to build such devices that ... a customized fashion. , "The project addressed a ...
(Date:4/17/2014)... 2014-- Colic affects about one in five infants in ... visits during the first several months after birth. Research ... showing promise; however, the April 1, 2014 issue of ... reported on a study, "Probiotics and Infant Colic," concluding ... for infant colic did not reduce crying ...
Breaking Medicine News(10 mins):Health News:Scientists discover brain's anti-distraction system 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Building 'smart' cell-based therapies 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2
... African Americans know and think little about lung cancer, African ... the disease that could interfere with prevention and treatment. Published ... the American Cancer Society, the report indicates that public health ... Lung cancer is the leading cause of cancer deaths ...
... , ... ... ... ...
... born as a result of assisted reproductive technologies since the ... While the majority of these children are healthy and normal, ... kinds of birth defects and being low birth weight, which ... in life. Carmen Sapienza, a geneticist at Temple University ...
... ... ... ... ...
... suggest , SATURDAY, Feb. 20 (HealthDay News) -- The ... for heart attack and heart failure and should be ... , The New York Times on Saturday ... Administration that find that if people now taking (rosiglitazone) ...
... ... company has already positioned itself as a powerful player in the online market of pure ... that can be purchased via creditcards! , ... (PRWEB) February 20, 2010 -- The war is raging in the online world ...
Cached Medicine News:Health News:Survey finds significant racial differences in lung cancer beliefs 2Health News:Live with Regis and Kelly Reveal A REVOLUTIONARY Pain Relief Method 2Health News:Live with Regis and Kelly Reveal A REVOLUTIONARY Pain Relief Method 3Health News:Tony Blair Visits Pioneering Interfaith Malaria Initiative in Nigeria 2Health News:Tony Blair Visits Pioneering Interfaith Malaria Initiative in Nigeria 3Health News:Tony Blair Visits Pioneering Interfaith Malaria Initiative in Nigeria 4Health News:Tony Blair Visits Pioneering Interfaith Malaria Initiative in Nigeria 5Health News:Tony Blair Visits Pioneering Interfaith Malaria Initiative in Nigeria 6Health News:Tony Blair Visits Pioneering Interfaith Malaria Initiative in Nigeria 7Health News:Remove Diabetes Drug Avandia From Market: FDA Reports 2Health News:Remove Diabetes Drug Avandia From Market: FDA Reports 3Health News:Remove Diabetes Drug Avandia From Market: FDA Reports 4Health News:Sun Spark Purity Moves Aggressively into the Market of Pure Lidocaine Powder and Caffeine Powder 2Health News:Sun Spark Purity Moves Aggressively into the Market of Pure Lidocaine Powder and Caffeine Powder 3
Inquire...
... A fast, reliable and accurate immunoassay ... and plasma. , ,The fully automated Elecsys ... failure in symptomatic patients. NT-proBNP levels also ... allow the assessment of prognosis. In addition, ...
... there is a more efficient way ... fully portable battery operated patient warming ... surgical teams with a compact and ... the entire surgical process. Its unique ...
... system consists of our compact and ... blankets for use with patients of ... Blankets are available for intra and ... sizes and a sterile cardiac blanket ...
Medicine Products: